Development of a 3-D Organoid System Using Human Induced Pluripotent Stem Cells to Model Idiopathic Autism

Lunden, Jason W; Durens, Madel; Nestor, Jonathan E.; Niescier, Robert F.; Herold, Kevin; Brandenburg, Cheryl; Lin, Yu‐Chih; Blatt, Gene J.; Nestor, Michael W.

doi:10.1007/978-3-030-45493-7_10

Cited by 3 publications

(1 citation statement)

References 83 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Autism spectrum disorder. Autism studies are discussed in depth in other reviews concerning 3D in vitro models of neurodevelopmental disorders [22,71,[168][169][170][171][172][173][174][175][176]. Here, we will focus on the utility of human stem cell models for non-syndromic idiopathic ASD, which comprises roughly 70% of cases.…”

Section: Environmental and Substance Abuse Acquired Cognitive Disordersmentioning

confidence: 99%

Advancing preclinical models of psychiatric disorders with human brain organoid cultures

Dixon

Muotri

2022

Mol Psychiatry

View full text Add to dashboard Cite

Psychiatric disorders are often distinguished from neurological disorders in that the former do not have characteristic lesions or findings from cerebrospinal fluid, electroencephalograms (EEGs), or brain imaging, and furthermore do not have commonly recognized convergent mechanisms. Psychiatric disorders commonly involve clinical diagnosis of phenotypic behavioral disturbances of mood and psychosis, often with a poorly understood contribution of environmental factors. As such, psychiatric disease has been challenging to model preclinically for mechanistic understanding and pharmaceutical development. This review compares commonly used animal paradigms of preclinical testing with evolving techniques of induced pluripotent cell culture with a focus on emerging three-dimensional models. Advances in complexity of 3D cultures, recapitulating electrical activity in utero, and disease modeling of psychosis, mood, and environmentally induced disorders are reviewed. Insights from these rapidly expanding technologies are discussed as they pertain to the utility of human organoid and other models in finding novel research directions, validating pharmaceutical action, and recapitulating human disease.

show abstract